登录 | 注册    关注公众号  
微信公众号
搜索
 > 【LILRB1】

LILRB1信息

英文名称:Leukocyte immunoglobulin-like receptor B1
中文名称:白细胞免疫球蛋白样受体B1
靶点别称:Leukocyte Immunoglobulin Like Receptor B1,LIR-1,MIR-7,ILT2,LIR1,Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1 Soluble Isoform,PIR-B,Leukocyte immunoglobulin-like receptor 1,MIR7,PIRB,CD85j,Immunoglobulin-like transcript 2,Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Member 1,Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1,Monocyte/Macrophage Immunoglobulin-Like Receptor 7,CD85 Antigen-Like Family Member J,Myeloid Inhibitory Receptor 7,
上市药物数量:0
临床药物数量:4
最高研发阶段:临床二期

抗体项目交易平台

项目名称 项目阶段 分子类型 分子来源 疾病领域 适应症

Licensing 项目合作

项目名称 药物类型 治疗领域 适应症 阶段 权益地区

LILRB1分子别名

CD85J,LILRB1,CD85,ILT2,LIR1,MIR7

LILRB1分子背景

CD85 antigen-like family member J (CD85J) is also known as Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1 or LIR-1), Immunoglobulin-like transcript 2 (ILT-2), Monocyte/macrophage immunoglobulin-like receptor 7 (MIR7), which belongs to leukocyte immunoglobulin-like receptor (LIR) family. CD85J / LILRB1 Contains 4 Ig-like C2-type (immunoglobulin-like) domains. CD85J / LIR-1 is expressed predominantly on B-cells and monocytes. CD85J is receptor for class I MHC antigens and recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles and is also receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. CD85J / LILRB1 interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. CD85J / LILRB1 inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
NGM-707 NGM-707 临床二期 Merck & Co, Ngm Biopharmaceuticals Inc 卵巢癌, 胃癌, 肾细胞癌, 头颈部鳞状细胞癌, 食道癌, 胶质母细胞瘤, 间皮组织肿瘤, 胆管上皮癌, 乳腺癌, 结直肠癌, 胰腺导管癌, 非小细胞肺癌, 宫颈癌, 黑色素瘤 详情
BND-22 BND-22; SAR-444881 临床二期 Biond Biologics Ltd, 赛诺菲 肿瘤 详情
IOS-1002 ios-H2 临床一期 ImmunOs Therapeutics AG 实体瘤, 血液肿瘤 详情
AGEN-1571 AGEN-1571 临床一期 安帝君斯公司 实体瘤, 肿瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定